it halted progression at the S phase through the ATR/Chk1 pathway, while in HCT-116 cells, it caused arrest at the G1 phase via the ATM/Chk2 pathway. This was accompanied by downregulation of key ...
it halted progression at the S phase through the ATR/Chk1 pathway, while in HCT-116 cells, it caused arrest at the G1 phase via the ATM/Chk2 pathway. This was accompanied by downregulation of key ...
Also referred to as prexasertib, Acrivon’s lead candidate ACR-368 is a selective small molecule inhibitor that targets checkpoint kinase 1(CHK1) and CHK2 ... crucial for pathway-based drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback